Filana Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Filana Therapeutics, Inc. carries a market capitalization of 48.79M, placing it among publicly traded companies globally. Its enterprise value stands at -4.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 48.79M |
| Enterprise Value | -4.93M |
Share Statistics
Filana Therapeutics, Inc. currently has 48.31M shares outstanding.
| Shares Outstanding | 48.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.16 |
| P/TBV Ratio | 1.20 |
| P/FCF Ratio | -2.79 |
| P/OCF Ratio | -2.74 |
Financial Position
Filana Therapeutics, Inc. maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.19 |
| Quick Ratio | 2.16 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -62.50 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Filana Therapeutics, Inc.'s stock has declined approximately -50.73171% over the past 52 weeks. The 50-day moving average sits at 1.26, while the 200-day moving average is 2.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50.73171% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 2.16 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -81.75M, while operating income came in at -82.71M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -82.71M |
| Pretax Income | -77.90M |
| Net Income | -77.90M |
| EBITDA | -81.75M |
| EBIT | -82.71M |
| Earnings Per Share (EPS) | -1.61 |
Balance Sheet
Total book value stands at -506.37M, with working capital of 47.85M providing operational flexibility.
| Cash & Cash Equivalents | 86.57M |
| Total Debt | N/A |
| Net Debt | -86.57M |
| Equity (Book Value) | -506.37M |
| Book Value Per Share | -10.48 |
| Working Capital | 47.85M |
Cash Flow
Filana Therapeutics, Inc. produced -29.79M in operating cash flow over the past twelve months. After subtracting -581,000.00 in capital expenditures, free cash flow totaled -30.37M - equivalent to -0.63 per share.
| Operating Cash Flow | -29.79M |
| Capital Expenditures | -581,000.00 |
| Free Cash Flow | -30.37M |
| FCF Per Share | -0.63 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.47 |
| FCF Yield | -35.78 |
Scores
Filana Therapeutics, Inc. posts an Altman Z-Score of -7.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.31 |